5 Therapies|Clear filters
Reg. name: Rydapt®
Class: Multi-targeted Tyrosine Kinase Inhibitor (TKI)
RYDAPT® is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation positive, as detected by a FDA approved test.